Diabetic neuropathy: new perspectives on early diagnosis and treatments
Authors
Sarik Hopek
Instituto Mexicano del Seguro Social. Delegación Quintana Roo. Grupo de Investigación Clínica del IMSS en Quintana Roo (GRICIQ)
Guroan Siniak
Instituto Mexicano del Seguro Social. Delegación Quintana Roo. Grupo de Investigación Clínica del IMSS en Quintana Roo (GRICIQ)
Keywords:
DPN, Type 1 diabetes, hyperglycemia
Abstract
Diabetic peripheral neuropathy (DPN) is a complex disorder with many etiologies affecting about 50% of people with diabetes, and about 30% of diabetic neuropathy causes pain. Neuropathy can also develop in animal subjects and models prediabetes / insulin resistance, but not excessively hyperglycemia. At this time, there are no known treatments and Good glycemic control slows the progression of DPN in type 1 diabetes, but not type 2 diabetes [1]. Annual cost for Healthcare for DPN patients in the United States is staggering with estimates in excess of $ 15 billion [2]. Given increased incidence of type 1 and type 2 diabetes and obesity and the impact of DPN on your quality of life patients and their families and overall healthcare costs, a strategy for early diagnosis and discovery Treatment is needed.
